Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

ARK Genomic Revolution Multi-Sector ETF

Beam Therapeutics

Caribou Biosciences

Editas Medicine

Robinhood

Eli Lilly

Intellia Therapeutics

Prime Medicine Inc

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

Intuitive Surgical

Pfizer

Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- are a good place to start.

5 Top Stocks to Buy Before 2024

AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovation. AI is turbocharging techniques like CRISPR and Prime Editing, opening doors to previously unimaginable genetic breakthroughs. In the AI-enhanced biotech arena, traditional valuation metrics are old news. Speed, efficiency, and the ability to leapfrog development stages redefine how we value these trailblazing firms.

AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?

Amazon

ARK Innovation ETF

Coinbase

Microsoft

NVIDIA

Roku

Block

Twist Bioscience Corp

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

5 Best Performing Stocks of the Top ETF of November

Ginkgo Bioworks Holdings

These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.

Looking for Growth? 2 Top Stocks to Buy Hand Over Fist

Arcellx

In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.

3 Biotech Stocks That Could Be Multibaggers in the Making

Does CRISPR Therapeutics AG (CRSP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why CRISPR Therapeutics AG (CRSP) is a Great Momentum Stock to Buy

Crispr just executed on a moonshot goal, winning U.K. approval for the first-ever gene-editing treatment and sending CRSP stock sky-high.

What's Next For Gene-Editing Darling Crispr After Its 'Historic' First-Ever Approval?

Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline targeting various genetic diseases and conditions. CRSP focuses on ex vivo gene editing and has a diverse pipeline targeting different therapeutic areas, including hemoglobinopathies, immuno-oncology, and regenerative medicine.

CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics

Transmedics Group Inc

Amazon has plenty of room to grow despite its already huge size. CRISPR Therapeutics is at a pivotal point, with U.S. approvals for its lead candidate potentially on the way.

Investing in These 3 Stocks Now Could Make You a Millionaire Retiree

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility. Major publicly traded CRISPR companies include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Caribou Biosciences, and Prime Medicine.

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the United Kingdom.

CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why

ACADIA Pharma

Dynavax Technologies

Gilead Sciences

Ligand Pharmaceuticals

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright

First-mover advantages are a big deal in the world of pharmaceuticals. CRISPR Therapeutics scored the first-ever regulatory approval for a CRISPR/Cas9 treatment this month.

Is CRISPR Therapeutics the Best Gene-Editing Stock?

Axsome Therapeutics

Moderna

There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies and hold onto those shares for the long term.

3 Biotech Stocks That Could Be Millionaire Makers

Applied Optoelectronics

Golden Heaven Group Holdings Ltd

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

These Stocks Are Exploding In The November Stock Market Rally

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to Trade

Clearsign Combustion

QuantumScape

The hype around artificial intelligence has settled down a bit lately as people get used to the technology, but there's still a fascination with what these systems can do. One area of great interest is using AI to pick stocks.

Google's Bard AI Says These 3 Stocks Will Rise 1,000%

CRISPR Therapeutics is on the rise after scoring the world's first authorization for a CRISPR-based gene editing treatment. The product, a potentially curative option for hard-to-treat blood disorders, could become a blockbuster.

Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?

CRISPR Therapeutics stock continued to rise after the company received U.K. approval for Casgevy (exa-cel). The company and its partner, Vertex Pharmaceuticals, could have more good news on the way.

Why CRISPR Therapeutics Stock Is Jumping Again Today

Archer Aviation

Palantir Technologies

Cathie Wood is as bullish as ever, but recent economic indicators point to strength for her favorite stocks. In an interview, Cathie Wood emphasized that deflation is now a key concern rather than inflation.

3 Cathie Wood You'll Regret Not Buying Soon: November 2023

CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.

CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy

In a world first, regulators in the UK approved Crispr's gene-editing treatment for two blood diseases on Thursday, and CRSP stock surged.

Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug

Shares of Crispr Therapeutics CRSP, +1.68% and Vertex Pharmaceuticals Inc. VRTX, -5.57% gained ground premarket on Thursday after the companies got the world's first regulatory authorization for a medicine based on CRISPR, the transformative gene-editing technology.

Crispr Therapeutics, Vertex get world's first regulatory green light for CRISPR-based medicine

CRISPR Therapeutics (NASDAQ: CRSP ) stock rose 5% on news the U.K. gave conditional marketing authority to its gene therapy for sickle cell anemia. It's the first authorization in the world for the CRISPR gene-editing technology.

CRISPR Therapeutics (CRSP) Stock Jumps as U.K. Authorizes Gene Therapy

News for CRISPR Therapeutics Stock (CRSP)